synaptogenesis raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-09-05. Anything still debated is marked as such rather than presented as settled.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Structural features include amino acid residues and a hexanoic acid group. |
| Common synonyms | PNB-0408; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Names vary by source and should be verified. |
| Origin | Angiotensin IV research | Developed as a modified analog in academic laboratories. |
| Primary research focus | Synaptic growth and cognition | Studied mainly in cultured neurons and rodent models. |
| Regulatory status | Not approved as a drug | No accepted human therapeutic or supplement status. |
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
In 2024, McGregor and Boorman – with their principal support crew from the previous Long Way journeys – undertook a fourth international trip, this time on a 1974 Moto Guzzi Eldorado police motorcycle, while Boorman chose a BMW R75/5. This was documented in the 2025 series Long Way Home.
==== Copycat suicides and romanticisation ==== Another negative effect that misrepresentation of mental illnesses through the news can cause is copycat suicide. As with the deaths of celebrities Kate Spade and Robin Williams, an abundance of media and news coverage occurs. A Columbia University study revealed that "suicides rose nearly 10% higher than expected in the months following Robin Williams' death in August 2014," especially involving the method used by Robin Williams himself (a 32% increase). These results support the idea of suicide contagion, which the U.S. Department of Health & Human Services (HHS) defines as "the exposure to suicide or suicidal behaviors within one's family, one's peer group, or through media reports of suicide and can result in an increase in suicide and suicidal behaviors." A notable mid-2010s case of modern digital media contagion is the 2015 suicide of 16-year-old Russian student Renata Kambolina (known online under the pseudonym Rina Palenkova). After posting a final trackside selfie with the caption "nya. bye." ("ня.пока."), her tragic death rapidly went viral on the Russian social network VKontakte. This sparked a dangerous wave of romanticisation that falsely framed her as a virtual idol, prompting numerous vulnerable youths to replicate either her final words, her exact photo framing, or both, during their own suicides or attempted suicides—notably Gleb Korablyov in 2019. Like Kambolina, Korablyov also had his tragic death immediately seized upon and mythologised by internet trolls and morbid online communities.
Hemolysis or increased breakdown of red blood cells (for example hematoma resorption) Intrahepatic causes can be associated with elevated levels of conjugated bilirubin, unconjugated bilirubin or both. They include:
Sources: en.wikipedia.org
=== Differentiation === Hemp juice can be clearly distinguished from other liquid products of the hemp plant. Hemp milk and hemp oil, just like soy milk, are produced from the seeds of the plant. Beverages such as hemp beer use the dried flowers or dried leaves of the plant. When dried parts of hemp are used in water and extract results. Water extraction only contains a proportion of about 10% of hemp ingredients otherwise found in cold-pressed juice, therefore, cold-pressed hemp juice contains a much higher percentage of notable ingredients. More importantly, water extraction does not contain any of the important cannabinoids as they cling to the fatty acids of the plant, which are not dissolved in water extraction. That being said, cold-pressed hemp juice does contain the valuable cannabinoids. These valuable ingredients are also preserved when hemp is juiced in a conventional home blender. This process of juicing is not suitable for industrial hemp because the plant fibers used for industrial applications are too hard to digest for humans.
The highest dose of a drug or treatment that does not cause unacceptable side effects. The maximum tolerated dose is determined in clinical trials by testing increasing doses on different groups of people until the highest dose with acceptable side effects is found. Also called MTD. (NCI) Medication
On his retirement, Mahathir was named a Grand Commander of the Order of the Defender of the Realm, the highest honour in Malaysia, allowing him to adopt the title of "Tun". Under Mahathir's leadership, Malaysia was transformed into an industrialising nation. He pledged to leave politics "completely", rejecting an emeritus role in Abdullah's cabinet. Abdullah immediately made his mark as a quieter and less adversarial premier. With stronger religious credentials than Mahathir, he beat back PAS's surge in the 1999 election and lead the Barisan Nasional in the 2004 election to its biggest win ever, taking 199 of 219 parliamentary seats. On 23 October, Mingguan Malaysia, a Sunday edition of Utusan Malaysia, published an exclusive interview with Mahathir, marking his first since retiring as prime minister. After retiring, Mahathir maintained a busy schedule, engaging in various activities and speaking engagements both locally and internationally. In 2005, Russian president Vladimir Putin visited him at his private residence, where they held a four-hour meeting discussing Malaysia's economic transformation and development strategies. He emphasized the importance of staying active, stating, "Never retire. You have to work. When you work, it will keep you alive." His office at the Perdana Leadership Foundation and residence at the Mines Resort City, as well as expenses for meal allowances, escorts, bodyguards, a medical officer, and a special assistant during overseas trips, are funded by the government under the Member of Parliament (Remuneration) Act 1980 (Act 237).
== Electronic structure of the sugar-phosphate backbone == The sugar-phosphate backbone has multiplex electronic structure and the electron delocalisation complicates its theoretical description. Some part of the electronic density is delocalised over the whole backbone and the extent of the delocalisation is affected by backbone conformation due to hyper-conjugation effects. Hyper-conjugation arises from donor-acceptor interactions of localised orbitals in 1,3 positions.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide-like compound studied primarily in preclinical models. It is often classified as an angiotensin IV analog and has been investigated for effects on neuronal connectivity. It is not an approved drug or dietary supplement.
The exact mechanism is uncertain. Some research proposes activation of hepatocyte growth factor/c-Met signaling, while other evidence implicates insulin-regulated aminopeptidase. Multiple pathways may contribute, depending on the experimental system.
Published large-scale human trials are lacking. Most available data come from cell cultures and animal studies. As a result, human safety, appropriate dosing, and clinical effectiveness are not established.
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.